TABLE 3.
Baseline results.
| Strategies and scenarios | Total cost, $ | LYs | QALYs | ICER per LY | ICER per QALY |
|---|---|---|---|---|---|
| Sintilimab group | 100,097.40 | 12.51 | 8.81 | 5,721.08 | 7,819.66 |
| EFS state | 71,396.07 | 8.84 | 6.72 | - | - |
| PD state | 28,701.33 | 3.67 | 2.09 | - | - |
| Standard therapy group | 75,888.80 | 8.27 | 5.71 | - | - |
| EFS state | 40,446.13 | 5.24 | 3.98 | - | - |
| PD state | 35,442.67 | 3.03 | 1.73 | - | - |
Abbreviation: ICER, incremental cost-effectiveness ratio; LY, life-year; QALY, quality-adjusted life-year.